Bioporto Diagnostics Inc. Us

Acute kidney injury (AKI) is a common clinical syndrome among hospitalized patients, affecting 10-15% of hospitalized patients and 25-57% of those in intensive care units. It is often asymptomatic and can be difficult to identify, yet it can have severe short- and long-term consequences. To learn more about this public health concern, visit https://bioporto.us/aki/. Located outside Boston, BioPorto Diagnostics is focused on saving lives and improving the quality of life with actionable biomarkers – tools designed to help clinicians make changes in patient management. FDA-cleared ProNephro AKI™ (NGAL) is designed to aid in AKI risk assessment in patients ≥ 3 months to <22 years of age by providing quantitative determinations of the NGAL biomarker (neutrophil gelatinase-associated lipocalin). Learn more about ProNephro AKI™ (NGAL) at: https://bioporto.us/pronephro-aki/ Posts are intended for a U.S. audience. If you are from outside the United States, you are encouraged to visit to learn more about The NGAL Test™, which is CE-Marked for IVD use in the EU, and to follow BioPorto Diagnostics A/S on LinkedIn at Social Media Community Guidelines: https://bioporto.us/social-media